INRLF (Valneva SE) ROCE % : -7.60% (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Valneva SE ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Valneva SE's annualized ROCE % for the quarter that ended in Sep. 2024 was -7.60%.

Valneva SE ROCE % Historical Data

The historical data trend for Valneva SE's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE ROCE % Chart

Valneva SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

0.85

-22.86

-14.28

-30.59

-23.71

Valneva SE Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-36.75	-23.32	76.60	-21.38	-7.60

Valneva SE ROCE % Calculation

Valneva SE's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-82.12	/	( ( (658.203 - 293.849)	+	(501.703 - 173.242) )	/ 2 )
	=	-82.12	/	( (364.354	+	328.461)	/ 2 )
	=	-82.12	/	346.4075
	=	-23.71 %

Valneva SE's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-32.076	/	( ( (502.227 - 110.322)	+	(573.378 - 121.15) )	/ 2 )
	=	-32.076	/	( ( 391.905	+	452.228 )	/ 2 )
	=	-32.076	/	422.0665
	=	-7.60 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Valneva SE (OTCPK:INRLF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Valneva SE ROCE % Related Terms

Thank you for viewing the detailed overview of Valneva SE's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (OTCPK:INRLF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VALN:USA VLAp:UK 0OB3:UK VLA:France AYJ:Germany AYJ:Bulgaria VLA:Austria

Address

6 Rue Alain Bombard, Saint-Herblain, FRA, 44800

Website

https://www.valneva.com

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.